WEDNESDAY, Aug. 6, 2025 (HealthDay News) -- A proportion of men with grade group 1 (GG1) prostate cancer have a higher-risk disease than suggested by biopsy, according to a study published online July ...

Source: Getty Images To date, there is a lack of high-quality data comparing focal therapies to prostate cancer surgery or radiation. Focal therapy is emerging as a standard management strategy for ...

For patients with intermediate-risk, localized prostate cancer, radiation therapy delivered in five sessions reduced patient-reported side effects compared to longer courses of radiation, according to ...

Vascular-targeted photodynamic therapy continues to shows efficacy for partial gland ablation of intermediate-risk prostate cancer with minimal toxicity, according to long-term follow-up results from ...

People with localized prostate cancer treated according to guidelines developed by an international panel of doctors are more likely to die of something other than the disease, new research shows. A ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. For American men, prostate cancer is the most common cancer ...

Men treated for nonmetastatic prostate cancer under current guidelines are up to 6 times less likely to die from their cancer than from other causes, according to data from a Swedish cancer registry.

Plus, what's your risk of getting prostate cancer? Find out the latest figures on the disease below THOUSANDS more men should receive an existing prostate cancer drug on the NHS as research shows it ...

The US FDA has granted De Novo marketing authorization for ArteraAI Prostate (Artera, Los Altos, California), a novel artificial intelligence (AI)-powered risk-stratification tool for patients with ...